** Shares of rare neurological disease-focused pharma company Harmony Biosciences rise HRMY.O 3.5% to $31 premarket
** HRMY posts Q1 adj. profit of 78 cents per share, above analysts' estimate of 58 cents per share - data compiled by LSEG
** Company posts Q1 product revenue of $184.73 million, beating analysts' estimate of $182.9 million
** Company maintains its 2025 product revenue of $820 million to $860 million compared with estimates of $839.89 million
** As of last close, HRMY has fallen 12.9% YTD
(Reporting by Siddhi Mahatole)
((siddhi.mahatole@thomsonreuters.com))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.